ArticleOncoimmunology2021

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.

Elizabeth Dudnik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.